Tech Company Financing Transactions

Disc Medicine Funding Round

Disc Medicine closed a $62.50 funding round on 2/14/2023. Backers included Bain Capital Life Sciences, Access Biotechnology and OrbiMed.

Transaction Overview

Company Name
Announced On
2/14/2023
Transaction Type
Venture Equity
Amount
$62
Round
Undisclosed
Investors
Proceeds Purpose
Disc Medicine, Inc. a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced it has entered into a securities purchase agreement with certain investors resulting in an aggregate $62.5 million in gross proceeds through a registered direct offering.

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
150 Cambridgepark Dr. 103
Cambridge, MA 02140
USA
Phone
Undisclosed
Email Address
Overview
Disc Medicine is a hematology company harnessing new insights in hepcidin biology to address ineffective red blood cell production (erythropoiesis). Focused on the hepcidin pathway, the master regulator of iron metabolism, Disc is advancing first-in-class therapies to transform the treatment of hematologic disease.
Profile
Disc Medicine LinkedIn Company Profile
Social Media
Disc Medicine Company Twitter Account
Company News
Disc Medicine News
Facebook
Disc Medicine on Facebook
YouTube
Disc Medicine on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
John Quisel
  John Quisel LinkedIn Profile  John Quisel Twitter Account  John Quisel News  John Quisel on Facebook
Chief Financial Officer
Joanne Bryce
  Joanne Bryce LinkedIn Profile  Joanne Bryce Twitter Account  Joanne Bryce News  Joanne Bryce on Facebook
Chief Medical Officer
William Savage
  William Savage LinkedIn Profile  William Savage Twitter Account  William Savage News  William Savage on Facebook
Vice President
Srikanth Venkatraman
  Srikanth Venkatraman LinkedIn Profile  Srikanth Venkatraman Twitter Account  Srikanth Venkatraman News  Srikanth Venkatraman on Facebook
Vice President
Hua Yang
  Hua Yang LinkedIn Profile  Hua Yang Twitter Account  Hua Yang News  Hua Yang on Facebook
VP - Bus. Development
Jonathan Yu
  Jonathan Yu LinkedIn Profile  Jonathan Yu Twitter Account  Jonathan Yu News  Jonathan Yu on Facebook
VP - Regulatory Affairs
Sarah Tuller
  Sarah Tuller LinkedIn Profile  Sarah Tuller Twitter Account  Sarah Tuller News  Sarah Tuller on Facebook


 

 

Browse more venture capital transactions:

Prev: 2/14/2023: Aspire venture capital transaction
Next: 2/14/2023: Suite Studios venture capital transaction

 

Share this article

 


Where The Data Comes From

We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from company press releases and news coverage. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary